International Journal of Gynecological Cancer最新文献

筛选
英文 中文
A hidden passenger: teratoma concealed by polycystic kidneys. 隐藏的乘客:多囊肾隐藏的畸胎瘤。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-20 DOI: 10.1016/j.ijgc.2025.102678
Katherine Martinez Carmona, Pedro T Ramirez
{"title":"A hidden passenger: teratoma concealed by polycystic kidneys.","authors":"Katherine Martinez Carmona, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.102678","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102678","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102678"},"PeriodicalIF":4.7,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer. 晚期、低度浆液性卵巢癌激素治疗的使用和结果。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-20 DOI: 10.1016/j.ijgc.2025.102676
Katherine Yoh, Ling Chen, Xiao Xu, Jennifer S Ferris, Shayan Dioun, Alexandre Buckley de Meritens, Caryn M St Clair, Tarah Pua, Thomas Randall, June Y Hou, Dawn L Hershman, Jason D Wright
{"title":"Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer.","authors":"Katherine Yoh, Ling Chen, Xiao Xu, Jennifer S Ferris, Shayan Dioun, Alexandre Buckley de Meritens, Caryn M St Clair, Tarah Pua, Thomas Randall, June Y Hou, Dawn L Hershman, Jason D Wright","doi":"10.1016/j.ijgc.2025.102676","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102676","url":null,"abstract":"<p><strong>Objective: </strong>To examine trends in the use of hormonal therapy for advanced-stage, low-grade serous ovarian carcinoma and to compare survival outcomes of patients who received traditional chemotherapy, hormonal therapy alone, or the combination of both.</p><p><strong>Methods: </strong>Women with stage II to IV low-grade serous ovarian cancer diagnosed between 2011 and 2020 were identified from the National Cancer Data Base. Patients undergoing primary surgery followed by adjuvant chemotherapy, hormonal therapy, or both were included. A multinomial logistic regression model was used to examine factors associated with treatment. Propensity score-weighted Cox proportional hazards models (via inverse probability of treatment weighting) were applied to compare overall survival across the treatment groups.</p><p><strong>Results: </strong>Among 1532 women, 68.0% received chemotherapy alone, 12.3% received hormonal therapy alone, and 19.8% received combination therapy. Use of hormonal monotherapy increased from 0.8% in 2011 to 27.4% in 2020, and use of combination therapy increased from 0.8% to 32.6% (p < .001 for both). Hormonal therapy alone was more common in older patients (>70 years) (p = .001) and those with Medicare insurance (p < .001), while combination therapy was more common in women with stage III to IV disease (p = .001). After applying propensity score weighing, 5-year survival was 76.6% (95% CI 73.2% to 79.7%) for chemotherapy alone, 85.5% (95% CI 66.1% to 94.3%) for hormonal therapy alone, and 75.8% (95% CI 59.7% to 86.2%) for combination therapy. Compared to chemotherapy alone, the HR for all-cause mortality was 0.74 (95% CI 0.46 to 1.19) for hormonal therapy alone and 0.88 (95% CI 0.63 to 1.24) for combination therapy.</p><p><strong>Conclusions: </strong>In advanced-stage low-grade serous ovarian cancer, the use of hormonal therapy increased substantially over time. Comparable survival outcomes across modalities suggest hormonal therapy may be a viable treatment option, particularly for patients who will not tolerate the side effects of cytotoxic chemotherapy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102676"},"PeriodicalIF":4.7,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145292074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do dosing strategies alone explain survival differences in obese ovarian cancer patients? 单独用药策略能解释肥胖卵巢癌患者的生存差异吗?
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-20 DOI: 10.1016/j.ijgc.2025.102679
Xiyin Yang, Liyan Qi
{"title":"Do dosing strategies alone explain survival differences in obese ovarian cancer patients?","authors":"Xiyin Yang, Liyan Qi","doi":"10.1016/j.ijgc.2025.102679","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102679","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102679"},"PeriodicalIF":4.7,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to the comment by Signorelli et al. on the article "Correspondence on laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer: a 3-year cohort study by Marco D'Indinosante et al". 回复Signorelli等人对“腹腔镜肿瘤负荷作为晚期卵巢癌独立预后标志物的对应关系:Marco D’indinosante等人的3年队列研究”一文的评论。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-17 DOI: 10.1016/j.ijgc.2025.102670
Marco D'Indinosante, Denis Querleu, Anna Fagotti
{"title":"Reply to the comment by Signorelli et al. on the article \"Correspondence on laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer: a 3-year cohort study by Marco D'Indinosante et al\".","authors":"Marco D'Indinosante, Denis Querleu, Anna Fagotti","doi":"10.1016/j.ijgc.2025.102670","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102670","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102670"},"PeriodicalIF":4.7,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on "Silicon dioxide, sodium selenite and citric acid vaginal gel, HPV infection, and cervical preinvasive disease: a narrative review" by Emmanuel Sánchez Díaz. 关于“二氧化硅,亚硒酸钠和柠檬酸阴道凝胶,HPV感染和宫颈浸润前疾病:叙述回顾”的通信,作者:Emmanuel Sánchez Díaz。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-13 DOI: 10.1016/j.ijgc.2025.102669
Rene Pareja, Emmanuel Sánchez Díaz, Gabriel Levin
{"title":"Correspondence on \"Silicon dioxide, sodium selenite and citric acid vaginal gel, HPV infection, and cervical preinvasive disease: a narrative review\" by Emmanuel Sánchez Díaz.","authors":"Rene Pareja, Emmanuel Sánchez Díaz, Gabriel Levin","doi":"10.1016/j.ijgc.2025.102669","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102669","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102669"},"PeriodicalIF":4.7,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective comparison of resectability scores to enhance preoperative decision-making in the primary management of advanced ovarian cancer: a Memorial Sloan Kettering Cancer Center Team Ovary study. 在晚期卵巢癌的初步治疗中,可切除性评分提高术前决策的前瞻性比较:纪念斯隆-凯特琳癌症中心小组卵巢研究。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-12 DOI: 10.1016/j.ijgc.2025.102662
Ryan M Kahn, Kimberly Murphy, Kaothar Oladoja, Effi Yeoshoua, Lindsey Finch, Christina Harlev, Olga T Filippova, Alli M Straubhar, Renee A Cowan, Alexia Iasonos, Qin Zhou, Yulia Lakhman, Debra M Sarasohn, Nadeem R Abu-Rustum, Vance Broach, Ahmed Al-Niaimi, Ginger J Gardner, Yukio Sonoda, Oliver Zivanovic, Kara C Long, Dennis S Chi
{"title":"A prospective comparison of resectability scores to enhance preoperative decision-making in the primary management of advanced ovarian cancer: a Memorial Sloan Kettering Cancer Center Team Ovary study.","authors":"Ryan M Kahn, Kimberly Murphy, Kaothar Oladoja, Effi Yeoshoua, Lindsey Finch, Christina Harlev, Olga T Filippova, Alli M Straubhar, Renee A Cowan, Alexia Iasonos, Qin Zhou, Yulia Lakhman, Debra M Sarasohn, Nadeem R Abu-Rustum, Vance Broach, Ahmed Al-Niaimi, Ginger J Gardner, Yukio Sonoda, Oliver Zivanovic, Kara C Long, Dennis S Chi","doi":"10.1016/j.ijgc.2025.102662","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102662","url":null,"abstract":"<p><strong>Objective: </strong>To compare cytoreductive outcomes of 2 published algorithms used to triage patients with ovarian cancer to primary debulking surgery versus diagnostic laparoscopy or neoadjuvant chemotherapy.</p><p><strong>Methods: </strong>This prospective comparative study was conducted from August 1, 2021, to January 31, 2025. All patients with suspected advanced ovarian cancer who were eligible for primary debulking surgery on initial evaluation were identified. Imaging was reviewed utilizing a standardized radiology synoptic report. Data from the synoptic report were combined with clinical factors to determine a Resectability Score using 1 of 2 algorithms, Resectability Score 1.0 (RS1.0) and Resectability Score 2.0 (RS2.0). The algorithms include different clinical and radiologic variables; both generate low- and high-risk scores, with high-risk scores indicating a greater likelihood of suboptimal primary debulking surgery. In high-risk cases, laparoscopic evaluation of resectability was recommended, but management was based on surgeon's discretion.</p><p><strong>Results: </strong>Of 237 patients identified, 200 had primary debulking surgery with final pathology confirming epithelial ovarian carcinoma. Of 144 patients (72%) who underwent laparotomy and primary debulking surgery, 110 (76%) were triaged directly to surgery and 34 (24%) first underwent diagnostic laparoscopy; 120 (83%) had complete gross resection, 135 (94%) had residual disease ≤1 cm, and 9 (6%) had residual disease >1 cm. Of 56 patients (28%) who underwent neoadjuvant chemotherapy, 43 (77%) first underwent diagnostic laparoscopy, and 13 (23%) were triaged directly to chemotherapy. Among all patients, 44 (22%) had high-risk scores using RS1.0 and 54 (27%) using RS2.0. RS2.0 more frequently predicted the ability to and inability to achieve complete gross resection (p > .05). RS2.0 more accurately identified high-risk disease warranting neoadjuvant chemotherapy (p = .035). Most surgeons (73%) preferred RS2.0, citing ease of use and faster calculation time.</p><p><strong>Conclusions: </strong>RS2.0 demonstrated favorable predictive accuracy for complete gross resection and was preferred among surgeons. The favorable complete gross resection rate (83%) highlights the value of individualized preoperative triage for primary debulking surgery versus neoadjuvant chemotherapy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102662"},"PeriodicalIF":4.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of the sentinel lymph node mapping algorithm for patients with locally advanced endometrial carcinoma. 局部晚期子宫内膜癌前哨淋巴结定位算法的结果。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-10 DOI: 10.1016/j.ijgc.2025.102651
Allan Huang, Nawar A Latif, Stefan Gysler, Emily M Ko, Robert L Giuntoli, Sarah H Kim, Dimitrios Nasioudis
{"title":"Outcomes of the sentinel lymph node mapping algorithm for patients with locally advanced endometrial carcinoma.","authors":"Allan Huang, Nawar A Latif, Stefan Gysler, Emily M Ko, Robert L Giuntoli, Sarah H Kim, Dimitrios Nasioudis","doi":"10.1016/j.ijgc.2025.102651","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102651","url":null,"abstract":"<p><strong>Objective: </strong>Investigate the utilization and oncologic outcomes of the sentinel lymph node algorithm for patients with locally advanced endometrial cancer (involvement of the cervix, vagina, ovary, or parametria) (International Federation of Gynecology and Obstetrics stage II-IIIB).</p><p><strong>Methods: </strong>Patients diagnosed between 2012 and 2015 with endometrial carcinoma who underwent minimally invasive hysterectomy and had endocervical (T2), serosal/adnexal (T3A), or vaginal/parametrial involvement (T3B) and no distant metastases (M0) were identified in the National Cancer Database. Those who underwent sentinel lymph node biopsy (with or without lymphadenectomy) or systematic lymphadenectomy alone (defined as at least 20 lymph nodes removed) were included. Based on pathology reports, the incidence of lymph node metastases was compared with the χ<sup>2</sup> test. Overall survival was evaluated using Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to evaluate survival after controlling for confounders.</p><p><strong>Results: </strong>A total of 2108 patients were identified; 1786 (84.7%) had systematic lymphadenectomy (of whom 78.1% had para-aortic lymphadenectomy) with a median of 26 lymph nodes removed, while 322 (15.3%) patients underwent sentinel lymph node biopsy. The rate of lymph node metastases was 35.8% in the systematic lymphadenectomy group and 32.6% in the sentinel lymph node biopsy group, P = .27. Rates of adjuvant chemotherapy (59.7% vs 62.4%, p = .36) and radiation therapy (61.5% vs 58.7%, p = .34) were comparable. Patients who had systematic lymphadenectomy were less likely to be discharged within 1 day of surgery (66.4% vs 78.6%, p < .001). There was no overall survival difference between patients who had sentinel lymph node biopsy and those who had systematic lymphadenectomy (p = .60; 4-year overall survival rates were 71.5% and 73.9%, respectively), even after controlling for confounders (HR 1.08, 95% CI 0.82 to 1.41).</p><p><strong>Conclusions: </strong>Patients with locally advanced endometrial cancer have a high incidence of lymph node metastases. For these patients, sentinel lymph node biopsy is associated with overall survival similar to that of systematic lymphadenectomy.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102651"},"PeriodicalIF":4.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145292094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authors' response to: "Methodological concerns regarding AGO score validation in low-grade ovarian cancers". 作者对“低级别卵巢癌AGO评分验证的方法学问题”的回应。
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-10 DOI: 10.1016/j.ijgc.2025.102658
Emel Canaz, Eser S Ozyurek, Jalid Sehouli
{"title":"Authors' response to: \"Methodological concerns regarding AGO score validation in low-grade ovarian cancers\".","authors":"Emel Canaz, Eser S Ozyurek, Jalid Sehouli","doi":"10.1016/j.ijgc.2025.102658","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102658","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102658"},"PeriodicalIF":4.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study. 5天甲氨蝶呤与脉冲放线菌素D治疗低风险妊娠滋养细胞瘤的疗效和安全性比较:一项单中心历史队列研究
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-10 DOI: 10.1016/j.ijgc.2025.102657
Eri Katayama, Hirokazu Usui, Natsuko Nakamura, Asuka Sato, Nozomi Sakai, Satoyo Otsuka, Rie Okuya, Yuji Habu, Ayumu Matsuoka, Kyoko Nishikimi, Shinichi Tate, Kaori Koga
{"title":"Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study<sup>☆</sup>.","authors":"Eri Katayama, Hirokazu Usui, Natsuko Nakamura, Asuka Sato, Nozomi Sakai, Satoyo Otsuka, Rie Okuya, Yuji Habu, Ayumu Matsuoka, Kyoko Nishikimi, Shinichi Tate, Kaori Koga","doi":"10.1016/j.ijgc.2025.102657","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102657","url":null,"abstract":"<p><strong>Objective: </strong>In 2019, our institution changed the first-line regimen for low-risk gestational trophoblastic neoplasia from 5-day methotrexate (MTX) (20 mg × 5 days, intramuscular injection) to pulse actinomycin D (1.25 mg/m<sup>2</sup> intravenous) every 14 days. We compared the efficacy and safety of these regimens.</p><p><strong>Methods: </strong>Between 2007 and 2022, 105 low-risk gestational trophoblastic neoplasia cases were identified. The patients' background, outcomes, and adverse effects were analyzed retrospectively using the Mann-Whitney U test, Fisher's exact test, and propensity score-matching analyses.</p><p><strong>Results: </strong>Among the patients, 83 were treated before 2019 (MTX group), and 22 were treated after 2019 (actinomycin D group). Age and pre-treatment human chorionic gonadotropin levels were comparable between the groups. However, the International Federation of Gynecology and Obstetrics score was significantly greater in the MTX group (p < .05). The primary remission rate was significantly greater in the actinomycin D group (81.8%, 18/22) than in the MTX group (38.6%, 32/83, p < .01). Drug resistance was observed in 24.1% (20/83) and 18.2% (4/22) of patients in the MTX and actinomycin D groups, respectively (p = .78). The superior effects of actinomycin D were also observed in the analysis of matched patient backgrounds, including age, human chorionic gonadotropin levels, and International Federation of Gynecology and Obstetrics scores (p < .05). Severe adverse effects requiring a change in chemotherapy were reported in 37.3% (31/83) of the patients in the MTX group but none in the actinomycin D group.</p><p><strong>Conclusions: </strong>Pulse actinomycin D was more effective and safer than 5-day MTX. Considering the convenience of fewer hospital visits, the pulse actinomycin D regimen is a better option for low-risk gestational trophoblastic neoplasia in the Japanese population.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102657"},"PeriodicalIF":4.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on "Laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer: a 3-year cohort study" by Marco D'Indinosante et al. Marco D'Indinosante等人的“腹腔镜肿瘤负荷作为晚期卵巢癌独立预后指标:一项为期3年的队列研究”
IF 4.7 2区 医学
International Journal of Gynecological Cancer Pub Date : 2025-09-09 DOI: 10.1016/j.ijgc.2025.102659
Mauro Signorelli, Matteo Secchi, Giuseppe Vizzielli
{"title":"Correspondence on \"Laparoscopic tumor load as an independent prognostic marker in advanced ovarian cancer: a 3-year cohort study\" by Marco D'Indinosante et al.","authors":"Mauro Signorelli, Matteo Secchi, Giuseppe Vizzielli","doi":"10.1016/j.ijgc.2025.102659","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.102659","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"102659"},"PeriodicalIF":4.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信